Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation
Key Highlights
- ➤Kidney biopsies increased collagen IV abundance in all three Phase 2a participants
- ➤Podocyte foot process widths fell 46%, 14% and 16% after treatment
- ➤Exaluren produced 50% mean filtration slit-density increase, exceeding 80% of healthy controls
- ➤Exaluren had no serious adverse events, nephrotoxicity or ototoxicity in eight weeks
- ➤EXACT Phase 2b topline data expected mid-2027; 32-week data by end-2027
Expert Statements
Daniel P. Gale, MD, PhD, Department of Renal Medicine, University College London; lead author
“To our knowledge, this is the first demonstration in humans that a genetically targeted readthrough therapy can restore production of a missing protein in kidney cells and improve cell structure in a genetic kidney disease.”
Daniel P. Gale, MD, PhD, Department of Renal Medicine, University College London; lead author
“These findings provide a strong rationale for further clinical evaluation of this approach, including in the ongoing EXACT study.”
Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation PR Newswire
* First-in-human evidence of exaluren-mediated readthrough of collagen IV in patients with nonsense mutation Alport syndrome * Kidney biopsies showed increased collagen IV abundance and partially improved podocyte morphology in all three participants * Exaluren was well tolerated, with no serious adverse events, nephrotoxicity or ototoxicity * Published findings support the ongoing Phase 2b EXACT study ARLINGTON, Mass., Nov. 18, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced the publication of results from its Phase 2a proof-of-mechanism study of exaluren in nonsense mutation Alport syndrome in the Journal of Clinical Investigation (JCI). The open-access paper, "Phase 2a study of readthrough therapy in nonsense mutation Alport syndrome," is available at https://www.jci.org/articles/view/208623 .
Get started
Create a free account to read the full story.
